has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback